EXTON, Pa., Dec. 4, 2017 /PRNewswire/ — Eli Lilly’s IL-17 inhibitor, Taltz (ixekizumab), received FDA approval for the treatment of adults with active psoriatic arthritis (PsA) on December 1, 2017. The new indication for the brand will bring increased competition to a market that has…
